Pacira BioSciences, Inc. PCRX Capital investments accrued but not yet paid

Capital investments accrued but not yet paid at other companies

Avanos MedicalAVNS

$400K-71.4%

AtriCureATRC

——

Other financials

Income statement

See full

Revenue$177.4M+5.0%

Gross profit$141.0M+4.7%

Operating income$6.9M+247%

Net income$2.9M-39.4%

EPS (diluted)$0.07-30.0%

Balance sheet

See full

Cash & equivalents$144.3M-49.1%

Total debt$411.2M+15.3%

Total equity$653.9M-18.1%

Total assets$1.2B-23.8%

Cash flow

See full

Operating cash flow$25.7M-27.6%

CapEx$2.7M-68.1%

Free cash flow$23.0M-14.7%

Valuation

See full

Market cap$942.78M-14.5%

Enterprise value$1.21B+2.6%

P/E183.5×—

P/S1.3×-0.3×

Profitability

See full

Gross margin79.3%+1.7pp

Operating margin3.3%—

Net margin0.7%—

FCF margin18.1%-4.6pp

Returns & leverage

See full

Return on equity0.7%—

Debt / equity0.6×+0.2×

Current ratio4.7×+2.3×

Where this comes from

Reported directly by Pacira BioSciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CapitalExpendituresIncurredButNotYetPaid.

The official record: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pacira BioSciences, Inc.'s capital investments accrued but not yet paid.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Pacira BioSciences, Inc.'s capital investments accrued but not yet paid?: Pacira BioSciences, Inc. (PCRX) reported capital investments accrued but not yet paid of $1.36M in Q1 2026.
How has Pacira BioSciences, Inc.'s capital investments accrued but not yet paid changed year-over-year?: Pacira BioSciences, Inc.'s capital investments accrued but not yet paid increased by 77.6% year-over-year, from $767K to $1.36M.